Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, 65, Tsuruma-cho, Showa-ku, Nagoya, Aichi, Japan.
Division of Clinical Genetics, Department of Laboratory Medicine, Lund University Graduate School of Medicine, Lund, Sweden.
Int J Clin Oncol. 2022 Oct;27(10):1660-1668. doi: 10.1007/s10147-022-02214-9. Epub 2022 Jul 30.
The aim of the present study was to investigate the incidence and hallmarks of long-term survivors of recurrent ovarian carcinoma (LTSROC) in a large-scale retrospective cohort of patients from a multicenter study group.
We performed a regional multicenter retrospective study between January 1986 and September 2021 using clinical data collected under the central pathological review system. Patients who underwent surgery for primary OC at diagnosis and developed recurrent tumors after the initial treatment were included. We defined LTSROC as patients who survived for 5 years or longer after initial tumor recurrence and examined factors affecting the long-term survival of ROC and outcomes of LTSROC.
We collected information on patients with malignant ovarian tumors and finally 657 of them that developed ROC were included in the study population. Sixty-eight (10.4%) patients were LTSROC while 399 (60.7%) were short-term survivors of recurrent ovarian carcinoma. In a multivariate logistic regression analysis, negative ascites cytology [odds ratio (OR) 1.865; 95% CI 1.026-3.393; p = 0.041] and a recurrence-free interval (RFI) of 1 year or longer (OR 2.896; 95% CI 1.546-5.425; p < 0.001) were identified as independent factors associated with LTSROC. Approximately 80% of LTSROC presented with solitary recurrent tumors. Furthermore, more than 50% of LTSROC underwent tumor debulking surgery for the first recurrent tumor with or without chemotherapy.
RFI of 1 year or longer and negative ascites cytology in the initial surgery were identified as independent predictive factors for LTSROC.
本研究旨在通过对一个多中心研究组的大型回顾性队列中的复发性卵巢癌(LTSROC)长期幸存者的发病率和特征进行调查。
我们进行了一项区域性多中心回顾性研究,研究时间为 1986 年 1 月至 2021 年 9 月,使用中央病理审查系统收集的临床数据。纳入在诊断时接受原发性 OC 手术且在初始治疗后出现复发性肿瘤的患者。我们将 LTSROC 定义为在初始肿瘤复发后存活 5 年或更长时间的患者,并检查影响 ROC 长期生存和 LTSROC 结局的因素。
我们收集了患有恶性卵巢肿瘤的患者信息,最终纳入了研究人群中的 657 名出现 ROC 的患者。68 名(10.4%)患者为 LTSROC,399 名(60.7%)为复发性卵巢癌的短期幸存者。在多变量逻辑回归分析中,阴性腹水细胞学[比值比(OR)1.865;95%置信区间(CI)1.026-3.393;p=0.041]和 1 年或更长的无复发生存期(RFI)(OR 2.896;95%CI 1.546-5.425;p<0.001)被确定为与 LTSROC 相关的独立因素。大约 80%的 LTSROC 表现为单一复发性肿瘤。此外,超过 50%的 LTSROC 对首次复发性肿瘤进行肿瘤减瘤手术,无论是否联合化疗。
初始手术中 RFI 为 1 年或更长时间和阴性腹水细胞学被确定为 LTSROC 的独立预测因素。